JoshuaDavidRovinMD

Aortic Surgery, Cardiovascular Surgery

Director, Center for Advanced Valve and Structural Heart Care at Morton Plant Hospital Director of Transcatheter and Aortic Therapies, Morton Plant Hospital

Join to view full profile

Dr. Rovin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rovin's full profile

Already have an account?

Office
455 Pinellas St
Suite 320
Clearwater, FL 33756
Phone+1 727-446-2273

Fax+1 727-441-4966

Summary

Dr. Joshua Rovin is board certified in thoracic and cardiac surgery, and in general surgery. He has extensive experience in valve repair, thoracic aortic surgery, valve sparing aortic root reconstruction, mitral valve treatment, minimally invasive surgery and advanced endovascular repair. Dr. Rovin is one of the founding members and director of the Morton Plant Hospital (MPH) Valve Clinic, whose team was the first in Tampa Bay to perform a transcatheter aortic valve replacement (TAVR) for patients with severe aortic stenosis and transcatheter (TMVR and MitraClip) treatments for mitral disease . He is also director of Transcatheter and Aortic Therapies at MPH.

Education & Training

University of Virginia Medical Center2003 - 2005
University of Virginia Medical CenterChief Residency, Surgery, 2002 - 2003
University of Virginia Medical CenterResidency, Surgery, 1997 - 2002
University of Virginia Medical CenterInternship, Surgery, 1996 - 1997
University of Louisville School of MedicineClass of 1996

Certifications & Licensure

VA State Medical License 1996 - 2026
FL State Medical License 2005 - 2025
American Board of Surgery Surgery
American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons

Clinical Trials

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI). Start of enrollment: 2012 Apr 01
Active, not recruiting
Not Applicable
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS Start of enrollment: 2012 Aug 01
Active, not recruiting
Not Applicable
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial Start of enrollment: 2014 May 01
Recruiting
Not Applicable
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement Start of enrollment: 2014 Sep 22
Terminated
Not Applicable
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation Start of enrollment: 2016 Jun 01
Completed
Not Applicable
PARTNER II Trial: S3iCAP Start of enrollment: 2015 Jan 01
Completed
Not Applicable
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients Start of enrollment: 2016 Mar 01
Active, not recruiting
Not Applicable
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. Start of enrollment: 2017 Oct 23
Recruiting
Not Applicable
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study Start of enrollment: 2018 Oct 30
Active, not recruiting
Not Applicable
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement Start of enrollment: 2019 Jun 10
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2073 citations
Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients
Jeffrey J. Popma, G. Michael Deeb, Steven J. Yakubov, Mubashir Mumtaz, Hemal Gada
The New England Journal of Medicine. 2019-03-16
119 citations
Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aort...
Ted Feldman, Michael J. Reardon, Vivek Rajagopal, Raj Makkar, Tanvir Bajwa
JAMA. 2018-01-02
57 citations
Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement: REFLECT II.
Tamim Nazif, Jeffrey W. Moses, Rahul Sharma, Abhijeet Dhoble, Joshua Rovin
JACC. Cardiovascular Interventions. 2021-03-08

Journal Articles

Five Year Outcomes from the US Pivotal Trial of Valiant Captivia Stent Graft for Blunt Aortic Injury
Himanshu J Patel, Ali Azizzadeh, Omaida C Velazquez, Joshua D Rovin, Joseph V Lombardi, Ali Khoynezhad, The Annals of Thoracic Surgery

Press Mentions

Morton Plant Hospital Marks Five Years of Performing TAVR SurgeriesFebruary 7th, 2017
TAVR as an Option for Intermediate-Risk Patients: Physicians RespondAugust 24th, 2016